
OTLK Stock Forecast & Price Target
OTLK Analyst Ratings
Bulls say
Outlook Therapeutics Inc. recently received marketing authorization for ONS-5010, a significant milestone marking its entry into the European Union and UK markets for treating wet age-related macular degeneration, which enhances its revenue potential. Although general and administrative expenses rose by 106.2% year-over-year to $11.9 million, this increase is indicative of the company's commitment to scaling operations and advancing its clinical pipeline, reflected in the substantial 113.3% surge in research and development expenses to $9.7 million. Positive results from the NORSE EIGHT trial, demonstrating noninferiority to a competitor product, alongside strategic collaborations aimed at supporting commercial launches, position Outlook Therapeutics favorably for future growth in the ophthalmic market.
Bears say
In the first quarter of 2024, Outlook Therapeutics reported a significant loss per share of $0.78, coupled with a widening operating loss to $21.6 million, which exceeded prior estimates and reflects deteriorating financial health. The results from the NORSE EIGHT clinical study were disappointing, as the company failed to meet critical non-inferiority endpoints, raising concerns about the viability of its lead product, ONS-5010. Additionally, potential regulatory hurdles could impede the commercialization process, and there are risks of shareholder dilution if the company necessitates equity financing to navigate its financial challenges.
This aggregate rating is based on analysts' research of Outlook Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OTLK Analyst Forecast & Price Prediction
Start investing in OTLK
Order type
Buy in
Order amount
Est. shares
0 shares